Results 21 to 30 of about 485 (159)
Acute migraine treatments in patients above age 65. [PDF]
HeadacheBackground Migraine remains a prevalent and disabling condition in older adults, yet there are limited data guiding acute treatment in patients over the age of 65 years. This population is often underrepresented in clinical trials and
Shah T +3 more
europepmc +2 more sources
Advances in pharmaceutic managements of migraine
Chinese Journal of Contemporary Neurology and Neurosurgery, 2022 Migraine is a neurovascular disorder with great burden so that effective abortive and preventive treatment is needed. Different from the previous choice of drugs based on clinical experience, the specific treatment targeting the pathogenesis of migraine ...
LI Yan⁃sheng
doaj +1 more source
, 2023 Background: For many years triptans have been the cornerstone of acute migraine treatment. Nevertheless, treatment with triptans may not always be initiated due to contraindications (seen in approximately one fifth of patients) or inadequate response ...
Souza, Marcio Nattan Portes +3 more
core +1 more source
New strategies for migraine treatment and prevention
Aktualności Neurologiczne, 2019 Migraine is a neurological disorder characterised by recurrent attacks of headache accompanied by vegetative symptoms. It is estimated that 11–12% of the world’s population suffers from migraine.
Waldemar Brola, Piotr Sobolewski
doaj +1 more source
Targets for migraine treatment:beyond calcitonin gene-related peptide
, 2021 PURPOSE OF REVIEW: Despite the development of several medications for the acute and preventive treatment of migraine, there are still many patients in whom lack of efficacy, tolerability, interactions or contraindications make other options necessary ...
Villar-Martínez, María Dolores +5 more
core +1 more source
The pharmacotherapeutic management of episodic and chronic migraine with gepants [PDF]
, 2023 The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment.
Vécsei László +7 more
core +1 more source
An update on migraine: current understanding and future directions [PDF]
, 2017 Migraine is a common brain disorder with high disability rates which involves a series of abnormal neuronal networks, interacting at different levels of the central and peripheral nervous system.
Messina R, Goadsby PJ, Puledda F
core +4 more sources
Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans. [PDF]
Clin Transl SciABSTRACT The aim of this study was to determine the cerebrospinal fluid (CSF) to plasma concentration ratio of atogepant. Healthy adult participants (N = 28) were enrolled into this phase 1, open‐label study and received atogepant 60 mg once daily for 8 days. Steady‐state atogepant concentrations were determined from CSF samples collected on Day 6 at 2
Boinpally RR, Trugman JM.
europepmc +2 more sources
Revista de Neurología, 2023 Migraine is a prevalent neurological condition characterised by disabling headache attacks. In recent decades, new drugs have been developed specifically for the acute and preventive treatment of migraine based on its pathophysiology. These include calcitonin gene-related peptide (CGRP) antagonists (CGRP) (gepants) and selective serotoninergic 5-HT1F ...
Pérez-Rodríguez, Abigail +6 more
openaire +2 more sources
The Journal of Headache and Pain, 2021 Background the interest of clinical reaseach in polymorphisms and epigenetics in migraine has been growing over the years. Due to the new era of preventative migraine treatment opened by monoclonal antibodies (mAbs) targeting the signaling of the ...
Damiana Scuteri +4 more
doaj +1 more source